Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. ATHE, CVKD, GDTC, IRD, MRNS, CALC, XCUR, VRCA, RLYB, and PULM

Should you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Alterity Therapeutics (ATHE), Cadrenal Therapeutics (CVKD), CytoMed Therapeutics (GDTC), Opus Genetics (IRD), Marinus Pharmaceuticals (MRNS), CalciMedica (CALC), Exicure (XCUR), Verrica Pharmaceuticals (VRCA), Rallybio (RLYB), and Pulmatrix (PULM). These companies are all part of the "pharmaceutical preparations" industry.

XTL Biopharmaceuticals vs.

Alterity Therapeutics (NASDAQ:ATHE) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability.

XTL Biopharmaceuticals received 74 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 71.82% of users gave XTL Biopharmaceuticals an outperform vote while only 62.50% of users gave Alterity Therapeutics an outperform vote.

CompanyUnderperformOutperform
Alterity TherapeuticsOutperform Votes
5
62.50%
Underperform Votes
3
37.50%
XTL BiopharmaceuticalsOutperform Votes
79
71.82%
Underperform Votes
31
28.18%

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Alterity TherapeuticsN/A N/A N/A
XTL Biopharmaceuticals N/A N/A N/A

Alterity Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 230.58%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than XTL Biopharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alterity Therapeutics
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
XTL Biopharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Alterity Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

In the previous week, Alterity Therapeutics' average media sentiment score of 0.00 equaled XTL Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Alterity Therapeutics Neutral
XTL Biopharmaceuticals Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alterity TherapeuticsN/AN/A-$12.54MN/AN/A
XTL BiopharmaceuticalsN/AN/A-$1.78MN/AN/A

Summary

XTL Biopharmaceuticals beats Alterity Therapeutics on 5 of the 9 factors compared between the two stocks.

Remove Ads
Get XTL Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XTLB vs. The Competition

MetricXTL BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8.23M$7.11B$5.72B$8.00B
Dividend YieldN/A2.72%4.89%4.03%
P/E RatioN/A6.3024.9018.90
Price / SalesN/A219.97401.45115.03
Price / CashN/A65.6738.0534.62
Price / Book3.136.387.274.15
Net Income-$1.78M$140.25M$3.19B$246.75M

XTL Biopharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XTLB
XTL Biopharmaceuticals
N/A$1.29
-30.9%
N/A+39.7%$8.23MN/A0.00N/AGap Down
ATHE
Alterity Therapeutics
2.4952 of 5 stars
$3.64
-3.7%
$8.00
+119.8%
+112.9%$31.82MN/A0.0010Positive News
CVKD
Cadrenal Therapeutics
2.6136 of 5 stars
$17.40
-8.4%
$32.00
+83.9%
N/A$31.02MN/A-2.614
GDTC
CytoMed Therapeutics
2.138 of 5 stars
$2.81
+0.4%
$5.00
+77.9%
+21.4%$30.74MN/A0.00N/APositive News
Gap Down
IRD
Opus Genetics
2.6968 of 5 stars
$0.97
-5.7%
$8.00
+723.2%
N/A$30.68M$8.38M-0.8914Upcoming Earnings
Gap Up
MRNS
Marinus Pharmaceuticals
4.1537 of 5 stars
$0.55
-0.2%
$4.79
+771.6%
-93.8%$30.32M$30.99M-0.22110Analyst Forecast
News Coverage
CALC
CalciMedica
2.2699 of 5 stars
$2.20
-0.9%
$18.00
+718.2%
-51.8%$29.66MN/A-2.0430
XCUR
Exicure
1.779 of 5 stars
$11.32
+19.8%
N/A+1,521.2%$29.50M$500,000.00-5.4750Gap Up
VRCA
Verrica Pharmaceuticals
3.966 of 5 stars
$0.64
-1.4%
$9.50
+1,384.1%
-87.3%$29.19M$9.21M-0.3540Upcoming Earnings
RLYB
Rallybio
2.4831 of 5 stars
$0.69
-4.3%
$9.75
+1,311.0%
-64.3%$28.67M$598,000.00-0.4340Upcoming Earnings
PULM
Pulmatrix
0.3268 of 5 stars
$7.79
-3.6%
N/A+255.0%$28.45M$10.01M-2.9520Positive News
Remove Ads

Related Companies and Tools


This page (NASDAQ:XTLB) was last updated on 3/11/2025 by MarketBeat.com Staff
From Our Partners